The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia.
Haemophilia
; 26 Suppl 5: 21-29, 2020 Aug.
Article
in En
| MEDLINE
| ID: mdl-32935399
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Health Care Costs
/
Drug Costs
/
Cost of Illness
/
Antibodies, Bispecific
/
Antibodies, Monoclonal, Humanized
/
Hemophilia A
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Humans
/
Male
Country/Region as subject:
Oceania
Language:
En
Journal:
Haemophilia
Journal subject:
HEMATOLOGIA
Year:
2020
Document type:
Article
Affiliation country:
Australia
Country of publication:
United kingdom